Ching-Hung Chang

Ching-Hung Chang is a seasoned scientist with extensive experience in molecular virology and genetic engineering. Currently serving as a Principal Associate Scientist at Kelonia Therapeutics since September 2022, responsibilities include managing the Molecular Virology Core, designing lentiviral plasmid constructs, and coordinating external collaborations for plasmid DNA production. Previous roles include Senior Associate Scientist at Oncorus, where RNA virus engineering techniques were employed, and positions at Synteny Therapeutics, Generation Bio, and Voyager Therapeutics, focusing on baculoviruses, cell transfection, and molecular cloning. Ching-Hung Chang holds a Ph.D. candidate status in Virology from Academia Sinica, alongside a Master's in Biochemistry and a Bachelor's in Chemistry.